uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Show others and affiliations
2015 (English)In: Cell Death and Disease, ISSN 2041-4889, E-ISSN 2041-4889, Vol. 6, e1794Article in journal (Refereed) Published
Abstract [en]

Two main causes of platinum resistance are mutation in the tumor suppressor gene TP53 and drug-induced increase in intracellular glutathione concentration. Mutations in TP53 occur in about 50% of human tumors. APR-246 (PRIMA-1(MET)) is the first clinical-stage compound that reactivates mutant p53 and induces apoptosis. APR-246 is a prodrug that is converted to the active compound methylene quinuclidinone (MQ), a Michael acceptor that binds to cysteine residues in mutant p53 and restores its wildtype conformation. Here, we show that MQ also binds to cysteine in glutathione, thus decreasing intracellular free glutathione concentration. We also show that treatment with APR-246 completely restores the cisplatin and doxorubicin sensitivity to p53-mutant drug-resistant ovarian cancer cells. We propose that this unique ability of APR-246/MQ to bind to cysteines in both mutant p53 and glutathione has a key role in the resensitization as well as in the outstanding synergistic effects observed with APR-246 in combination with platinum compounds in ovarian cancer cell lines and primary cancer cells. However, MQ binding to cysteines in other targets, for example, thioredoxin reductase, may contribute as well. Strong synergy was also observed with the DNA-damaging drugs doxorubicin and gemcitabine, while additive effects were found with the taxane docetaxel. Our results provide a strong rationale for the ongoing clinical study with APR-246 in combination with platinum-based therapy in patients with p53-mutant recurrent high-grade serous (HGS) ovarian cancer. More than 96% of these patients carry TP53 mutations. Combined treatment with APR-246 and platinum or other DNA-damaging drugs could allow dramatically improved therapy of a wide range of therapy refractory p53 mutant tumors.

Place, publisher, year, edition, pages
2015. Vol. 6, e1794
National Category
Cell Biology
Identifiers
URN: urn:nbn:se:uu:diva-259117DOI: 10.1038/cddis.2015.143ISI: 000357514700020PubMedID: 26086967OAI: oai:DiVA.org:uu-259117DiVA: diva2:843337
Available from: 2015-07-28 Created: 2015-07-27 Last updated: 2017-12-04Bibliographically approved

Open Access in DiVA

fulltext(1802 kB)202 downloads
File information
File name FULLTEXT01.pdfFile size 1802 kBChecksum SHA-512
a9fda1b52bb74ffcc7e88f9b1b7c7d081711a698fffd8b8e9755da186631a4aaa5026e8068e8846dac4c7c99899088b06002c296e2768938361ecab909871691
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Gullbo, JoachimHallberg, Anders

Search in DiVA

By author/editor
Gullbo, JoachimHallberg, Anders
By organisation
Experimental and Clinical OncologyCancer Pharmacology and Computational MedicineOrganic Pharmaceutical Chemistry
In the same journal
Cell Death and Disease
Cell Biology

Search outside of DiVA

GoogleGoogle Scholar
Total: 202 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 655 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf